Showing results (21-30 of 77) with videos related to

Sort By:
Pageof 8
Journal of Andrology|June 16, 2006
Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapyMarcello Maggio, Amanda Blackford, Dennis Taub, et al.
Cancers|September 13, 2025
Evaluating the Impact of Weekly Physical Performance Reports on Daily Physical Activity and Symptoms Among Cancer Survivors: Secondary Analysis of a Randomized Controlled TrialMingfang Li, Chitchanok Benjasirisan, Jingyu Zhang, et al.
Biologics : Targets & Therapy|August 27, 2009
Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastasesPeter J O'Brien, Rajeev Ramanathan, Jonathan M Yingling, et al.
Journal of Translational Medicine|February 25, 2010
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899Robert S DiPaola, Yu-Hui Chen, Mark Stein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2010
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized studyDaniel Keizman, Marianna Zahurak, Victoria Sinibaldi, et al.
Patient Education and Counseling|September 9, 2022
Physicians' use of plain language during discussions of prostate cancer clinical trials with patientsLuke Thominet, Lauren M Hamel, Fatmeh Baidoun, et al.
Cancer|September 12, 2008
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancerJoel B Nelson, William Love, Joseph L Chin, et al.
The Journal of Urology|September 18, 2009
Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapyPreetika Sharma, Amy Wisniewski, Milena Braga-Basaria, et al.
Oncotarget|July 16, 2014
Selective inhibitors of nuclear export (SINE) as novel therapeutics for prostate cancerJanet Mendonca, Anup Sharma, Hae-Soo Kim, et al.
Urologic Oncology|July 26, 2011
Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancerGlenn Liu, Yu-Hui Chen, Jill Kolesar, et al.
Pageof 8